Herspiegel’s Post

One of the big questions asked was, "What percentage of your pipeline is externally licensed?" In simpler terms, we wanted to know how much of the new drug developments come from working with other companies. Our panelists shared real-life stories and percentages showing how important these partnerships are. They explained that working together with other companies isn't just talk—it's a crucial way to bring new and better medicines to people. At our recent Global Headquarters launch event in Cambridge, MA, we hosted a fantastic panel discussion on "Transforming Pharma via External Partnerships." #PharmaPartnerships #DrugDiscovery #HealthcareInnovation #Collaboration

NEW Video 📽: One of the big questions asked was, "What percentage of your pipeline is externally licensed?"In simpler terms, we wanted to know how much of the new drug developments come from working with other companies. Our panelists shared real-life stories and percentages showing how important these partnerships are. They explained that working together with other companies isn't just talk—it's a crucial way to bring new and better medicines to people.At our recent Global Headquarters launch event in Cambridge, MA, we hosted a fantastic panel discussion on "Transforming Pharma via External Partnerships." #PharmaPartnerships #DrugDiscovery #HealthcareInnovation #Collaboration

https://lnkd.in/dM29mT7n 🖇 we bring a wealth of experience in early-phase research and a deep understanding of drug development, from initial stages through post-authorization. 🖇Our team offers strategic guidance tailored to the unique demands of each phase, ensuring you know what is required, when it’s needed, and how to achieve your objectives efficiently. 🖇The dynamic nature of Early Phase Drug Development demands creative and adaptive solutions. We excel at providing these solutions, adapting to the evolving needs of your program with agility and precision. 🖇Our expertise allows us to identify opportunities and overcome challenges, ensuring your pipeline development progresses smoothly. 🖇We pride ourselves on our ability to think critically and act decisively, offering a highly experienced skill set that supports your development goals. 🖇 As your trusted partner, we are committed to bringing innovative strategies and a collaborative approach to drive your success in the competitive landscape of drug development. #DrugDevelopment #PharmaceuticalResearch #EarlyPhaseResearch #ClinicalTrials #BiotechInnovation #PipelineDevelopment #AdaptiveSolutions #InnovativeHealthcare #CriticalThinking

🎙️✨ Why T&D Pharma? Hear It from Diana! ✨🎙️ "To be fair, I don’t get this question often, but when someone asks me why T&D Pharma, my answer is simple: Try us once, and you won’t need to ask again!" – Diana 💬 At T&D Pharma, we believe actions speak louder than words. From seamless partnerships to top-quality products, we let our results do the talking. 🚀 Curious to experience the T&D Pharma difference? Let us show you firsthand! 📧 Text us via business.development@td-pharma.de to start the conversation and explore how we can support your business. 🌍✨ Pharmacy Worldwide ✨🌍  

In the dynamic and highly competitive biopharma landscape, the journey to commercialization success is filled with complexities and challenges, with each step presenting unique hurdles. One way to eliminate some of these hurdles is team communication, called “enterprise thinking”. Read about this approach: https://ow.ly/nvKG50RfOPW

Global: M&A market update - a comprehensive analysis of deal activity and the outlook for the market from McKinsey & Company, a strategic partner to European Healthcare Investor Association (E.H.I.A.). Life sciences M&A shows new signs of life - after deal value in life sciences peaked in 2021 and plummeted as the pandemic ended, dealmaking in the sector revived in 2023. Acquiring pre-commercial biotech assets to fuel growth renewed deal success for pharmaceutical companies. Managing the portfolio to improve profitability provided the key for medical technology companies. The current year promises to be an active one for deals across the sector. #lifesciences #privateequity #healthcare Elisa Wunderlich Antonia PiersantiIan Lyons Elliott King Sebastian Sieler Gunjan Khanna

It’s really good to see performance of some pharma companies , They have 𝐬𝐞𝐭𝐬 𝐭𝐡𝐞 𝐛𝐚𝐫 𝐚𝐠𝐚𝐢𝐧: 𝐇𝐢𝐠𝐡𝐞𝐬𝐭 𝟓-𝐘𝐞𝐚𝐫𝐬 𝐂𝐀𝐆𝐑 𝐚𝐦𝐨𝐧𝐠 𝐓𝐨𝐩 𝟏𝟎𝟎 𝐏𝐡𝐚𝐫𝐦𝐚 𝐂𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐢𝐨𝐧𝐬 In the realm of pharma corporate growth, few companies has emerged again with boasting the highest 𝐂𝐀𝐆𝐑 (Compound Annual Growth Rate) among the top 100 Pharma Corporates for the past 5 years, as per PharmaTrac Data …

I want to extend my gratitude to Michael Rai for sharing the insightful BioXconomy Biopharma Partner Benchmarking Report 2024 which was designed to establish a current baseline on biotech and smaller biopharma views on pharma partnering. Here are some key takeaways that particularly resonated with me: -Market Trends: The report offers a strong overview of current market trends, highlighting increased M&A activity, the pivotal role of licensing, and a growing focus on therapeutic areas like immuno-oncology and rare diseases. -Strategic Consistency: I found the recommendation for maintaining a consistent strategy, regardless of market conditions, to be particularly insightful. This is a crucial mindset for biotech companies navigating market volatility while keeping their long-term goals on point. -M&A Interest Shift: The report highlights the shift in M&A interest from Phase III/commercial assets to higher-risk Phase II assets. This trend is especially relevant for smaller biotech firms, as it shows that big pharma is willing to take on more risk for potential high rewards. From my own dialogues with big pharma, I can also see a trend towards moving to even earlier, pre-clinical, assets. Thank you once again, Michael, for the dialogue and discussion. This is the first version of the Benchmarking Report, and I am looking forward to the release of the next version! #PartneringONE #MarketTrends #Biotech #Pharmaceuticals #Innovation

Last week, we hosted Paula van Hennik, Group Head for Clinical Regulatory Sciences at ProPharma, at the myTomorrows office for an educational #myTalks presentation. As part of her presentation, Paula unpacked the #MarketingAuthorisation process, touching upon the EU registration process, key similarities and differences between the EU and US, and the importance of benefit-risk decision-making. Some key insights: ✅ Pharma companies should start their drug development journey with the end goal in mind, considering reimbursement and pricing strategies early-on will increase the chances of success. ✅ A global drug development plan that combines EU and US regulatory strategy is vital for avoiding regional product specific requirement differences and reducing procedural timelines. ✅ Early interaction with statisticians, methodologists, regulators, and health technology assessment (HTA) bodies can further strengthen the scientific and executional feasibility of a development plan. We are grateful for Paula’s unique and relevant insights!

Bringing an FDA-approved drug to market can cost over $5 billion, factoring in the full R&D process and unsuccessful trials—highlighting the critical need for strong R&D investments and quality partnerships. Despite fluctuating markets, essential services and breakthrough assets will always attract capital. However, not all investments are equal. Choosing the right partner is vital for financial backing and shared alignment to navigate challenges and deliver life-saving treatments. The impact of a value-based PE partnership that provides management support, growth investment, and board advisory is invaluable. As patients increasingly demand innovative, effective therapies—raising R&D costs—our efforts must be resilient and ambitious. Each investment should advance science to meet patient needs and set therapies up for long-term success. I've had the privilege to work with leading PE firms dedicated to life sciences and human health, whose mission is to support those investing on behalf of the company. This partnership-driven approach has made a difference for me and for the companies that benefit from their expertise. https://lnkd.in/d3KcSBBv